We plan to apply the XCART technology platform to develop cell-based therapeutics targeting the unique B-Cell receptor on the surface of an individual patient’s malignant tumor cells for the treatment of B-Cell lymphomas, an area of significant unmet medical need. Non-Hodgkin lymphoma (NHL) is a cancer that originates in the lymphatic system, with approximately 75,000 new cases each year, and represents a $5 billion market opportunity.1

XCART Addresses Need in Current Lymphoma Treatment Paradigm

XCART: Proof of Mechanism in B-Cell Lymphoma2

Human CD8+ T cells were transduced with Lentiviral vectors coding for one of pepFL1-CAR, pepFL2-CAR, pepFL3-CAR or CD19-CAR constructs

Learn more about our XCART™ platform

  1. https://seer.cancer.gov/; 2: Crump, M et al. Outcomes in refractory diffuse large B-cell lymphoma: results from the international SCHOLAR-1 study. Blood 2017 Aug 3; 3: Market Reports World. GLOBAL NON-HODGKIN LYMPHOMA THERAPEUTICS MARKET - SEGMENTED BY TYPE OF TREATMENT - GROWTH, TRENDS AND FORECASTS (2018 - 2023); BioPharm Insight Surveillance, Epidemiology, and End Results (SEER) 9 registries, National Cancer Institute, 2017
  2. Stepanov A, et al. 14 November 2018. Autocrine-based selection of ligands for personalized CAR-T therapy of lymphoma. Sci Adv. 4(11):eaau4580